Awards/COOPERATIVE AGREEMENT (B)

$42,990,046

Department of Health and Human Services·National Institutes of Health

ACTION DATE—·SOURCEUSASPENDING·SOURCE IDASST_NON_UM1AI148452_075

Award description

VANDERBILT VACCINE AND TREATMENT EVALUATION UNIT

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Funds Vanderbilt's vaccine and treatment evaluation unit to conduct clinical research and testing of vaccines and therapeutics.

Sub-sectors

vaccine-developmentclinical-evaluationnih-research

Why this matters

Vaccine evaluation capacity is critical infrastructure for pandemic preparedness and rapid response to emerging infectious diseases.

Supply-chain signal

Signals demand for clinical trial infrastructure, laboratory equipment, and biopharmaceutical manufacturing partnerships.

U.S.–China competition angle

Vaccine development and evaluation capability is a strategic asset in global health competition and pandemic response leadership.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002070.

Period of performance

Start

2020-07-14

End

2026-11-30

Status

activein 197 days

Recipient

Other awards from this recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier ASST_NON_UM1AI148452_075.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.